Paxmedica engages bourne partners to explore future monetization of potential priority review voucher (prv)

Tarrytown, n.y., nov. 02, 2023 (globe newswire) -- via ibn --  paxmedica, inc. (nasdaq: pxmd ), a pioneering biopharmaceutical company focused on advancing treatments for neurologic disorders, has engaged bourne partners , a leading financial services firm specializing in the pharma, pharma services, and consumer health sectors. this marks an important step in paxmedica's efforts to explore potential monetization of a priority review voucher (prv) prior to filing the nda for pax-101 for the treatment of african sleeping sickness.
PXMD Ratings Summary
PXMD Quant Ranking